Related Experiment Video
Updated: Apr 28, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
High PMS2 Expression-Based Nomogram for Risk Stratification in Resected Hepatocellular Carcinoma: Application to
Wenchen Gong1,2, Ruyu Han1,3, Liyu Sun1,3
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China.
Elevated post-meiotic segregation increased 2 (PMS2) protein expression indicates poor prognosis in hepatocellular carcinoma (HCC) patients. High PMS2, along with other factors, can predict recurrence risk and guide personalized therapy decisions.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Hepatocellular carcinoma (HCC) has a poor prognosis due to limited recurrence risk markers.
- Accurate prognostic stratification is crucial for optimizing HCC treatment, including neoadjuvant and adjuvant therapies.
- The prognostic significance of elevated mismatch repair (MMR) protein expression, specifically post-meiotic segregation increased 2 (PMS2), remains unclear.
Purpose of the Study:
- To investigate the prognostic value of PMS2 overexpression in HCC.
- To develop an integrated predictive model for improved risk stratification and therapy selection in HCC patients.
Main Methods:
- Analysis of 173 HCC patients to assess the association between PMS2 expression and survival outcomes.
- Utilized cellular and animal models to confirm the role of PMS2 in HCC progression.
- Performed multivariate analysis and developed a nomogram incorporating PMS2, p-AKT, BCLC stage, and differentiation.
Main Results:
- Elevated PMS2 expression was significantly correlated with poorer disease-free survival (DFS) and overall survival (OS) (p < 0.001).
- High PMS2, high p-AKT, advanced BCLC stage, and poor differentiation were independent predictors of poor DFS.
- The developed nomogram effectively stratified patients into high- and low-risk groups (p < 0.001), showing good predictive performance.
Conclusions:
- PMS2 overexpression serves as a potential prognostic biomarker for HCC.
- The integrated predictive model offers a promising tool for personalized treatment planning in HCC.
- Exploratory analysis suggests high-risk patients may benefit more from neoadjuvant immunotherapy, warranting further investigation.
